Compare Adaptive Biotechnologies Corp (ADPT) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares International Treasury Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while iShares International Treasury Bond ETF trades at $40.55. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | IGOV | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $43.09 |
52-Week Low | $10.24 | $40.54 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
IGOV trades at $40.75, down 0.71% today, with a bearish technical signal driven by moving averages and key indicators like ADX signaling strong selling pressure. The stock lacks available fundamental data such as P/E and profit margins. Recent news highlights institutional interest, with DMC Group increasing its stake by 69.5% in Q1 2026, but also notes downside risks from global inflationary pressures affecting its bond holdings.
The outlook remains cautious due to technical bearishness and macroeconomic headwinds, though institutional accumulation may provide some support. Key risks include interest rate sensitivity and geopolitical tensions, warranting close monitoring of earnings and economic indicators for any turnaround signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
